|
PRKRIR expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.63846713974181E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
8.16602341302541E-12 |
| Normal-vs-Stage2 |
9.93390000258998E-08 |
| Normal-vs-Stage3 |
3.53717055645575E-13 |
| Normal-vs-Stage4 |
1.86817228353675E-12 |
| Stage1-vs-Stage2 |
7.340800E-01 |
| Stage1-vs-Stage3 |
4.393600E-02 |
| Stage1-vs-Stage4 |
2.816000E-02 |
| Stage2-vs-Stage3 |
3.144600E-01 |
| Stage2-vs-Stage4 |
1.565360E-01 |
| Stage3-vs-Stage4 |
5.636200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.15907283770866E-13 |
| Normal-vs-AfricanAmerican |
1.1253999999683E-06 |
| Normal-vs-Asian |
2.58629999638771E-08 |
| Caucasian-vs-AfricanAmerican |
9.968200E-01 |
| Caucasian-vs-Asian |
7.344400E-01 |
| AfricanAmerican-vs-Asian |
8.163400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
7.84927678409986E-14 |
| Normal-vs-Female |
2.08544292945589E-12 |
| Male-vs-Female |
8.023600E-02 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
3.05649949794429E-10 |
| Normal-vs-Age(41-60Yrs) |
1.4210854715202E-14 |
| Normal-vs-Age(61-80Yrs) |
1.58879576162008E-11 |
| Normal-vs-Age(81-100Yrs) |
1.019600E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
3.802200E-02 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
9.675800E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
6.237800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
9.704000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
8.712800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
8.907600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.909380E-01 |
| Classical-VS-Follicular |
1.983700E-02 |
| Classical-VS-Other |
1.409560E-01 |
| Classical-VS-Normal |
1.49159573581414E-11 |
| Tall-VS-Follicular |
8.318800E-01 |
| Tall-VS-Other |
4.061400E-01 |
| Tall-VS-Normal |
1.38460000131957E-08 |
| Follicular-VS-Other |
5.515600E-01 |
| Follicular-VS-Normal |
2.50269804880077E-11 |
| Other-VS-Normal |
9.82069999999613E-05 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
7.30526750203353E-13 |
| Normal-vs-N1 |
6.78557210420649E-12 |
| N0-vs-N1 |
2.246800E-01 |
|
|
